mini-Heart Platform for Drug Discovery

About NovoHeart

Novoheart is a pioneering biotechnology firm that has developed the world's first human heart-in-a-jar and a suite of bioengineered human heart constructs for preclinical research. Its proprietary mini-Heart Platform leverages human pluripotent stem cells to create functional cardiac tissues for modeling diseases and assessing drug toxicity and efficacy, aiming to reduce costs and time in drug development. The company operates primarily as a platform and services provider, supporting pharmaceutical partners in advancing candidates, with its technology having contributed to multiple Investigational New Drug (IND) applications. While likely pre-revenue or in early revenue stages, Novoheart is positioned at the intersection of regenerative medicine and cardiovascular research, addressing a critical need for more predictive human-relevant models.

Therapeutic Areas